An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
نویسندگان
چکیده
منابع مشابه
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
PURPOSE ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non-small cell lung cancer (NSCLC) harboring ROS1 fusions; however, cancers eventually develop crizotinib resistance due to acquired mutations such as G2032R in ROS1...
متن کاملCancer Therapy: Preclinical Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Purpose: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non–small cell lung cancer (NSCLC) harboring ROS1 fusions; however, cancers eventually develop crizotinib resistance due to acquired mutations such as G2032R in ROS...
متن کاملMolecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
PURPOSE Although ROS1-rearranged non-small cell lung cancer (NSCLC) is sensitive to crizotinib, development of resistance is inevitable. Here, we identified molecular alterations in crizotinib-resistant tumors from two NSCLC patients with the CD74-ROS1 rearrangement, and in HCC78 cells harboring SLC34A2-ROS1 that showed resistance to crizotinib (HCC78CR cells). EXPERIMENTAL DESIGN ROS1 kinase...
متن کاملPartial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer
We report on a 90-year-old male patient with a ROS1-translocated adenocarcinoma of the lung who was treated with crizotinib as first-line therapy. After 11 months of treatment, we noticed complete metabolic response as measured by (18)F-FDG-PET/CT scan and a partial response according to RECIST criteria. This patient indicates that ROS1 translocations are not restricted to young age, female gen...
متن کاملBiology of Human Tumors Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Purpose: Although ROS1-rearranged non–small cell lung cancer (NSCLC) is sensitive to crizotinib, development of resistance is inevitable. Here, we identifiedmolecular alterations in crizotinibresistant tumors from two NSCLC patients with the CD74–ROS1 rearrangement, and in HCC78 cells harboring SLC34A2–ROS1 that showed resistance to crizotinib (HCC78CR cells). Experimental Design: ROS1 kinase d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2016
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.04.001